Last mentioned: Mar 22, 2026
Commercial Launch
Target date for the market entry of palazestrant for ER+ breast cancer treatment.
Institutional Stake Disclosure
Reports surfaced regarding a significant $122 million position held by a major investor.
Price Target Hike
Wall Street analysts raised the price target for OLMA to $62.00, citing clinical optimism.
Earnings & SEC Filing
Olema reported quarterly results and filed an 8-K detailing its financial condition.
Olema Pharmaceuticals (OLMA) has delivered a massive 242% return over the past year, fueled by clinical progress in its lead breast cancer candidate, palazestrant. A recent $122 million institutional position has sparked debate over whether the biotech firm still has significant room for growth ahead of a projected 2027 launch.
This page surfaces every story mentioning Palazestrant across our finance coverage. We track each entity's appearance over time so readers can trace how the narrative evolves — which developments are isolated incidents, which build into longer arcs, and which reframe how operators in the space think about the entity. Story selection uses the same multi-source verification gate applied across the rest of our coverage.
Read our editorial methodology for how we identify, deduplicate, and score entity references. Our glossary defines the technical terms used across stories on this page, and our trends index contextualizes individual developments against the longer-running finance beat. Cross-entity comparisons live on our compare view.
| What you see | What it tells you |
|---|---|
| Story count | Number of distinct stories where Palazestrant was a primary or referenced actor. |
| Recency clustering | Whether mentions are concentrated in a recent window (a news cycle) or distributed (a sustained arc). |
| Sentiment distribution | Aggregate sentiment of the stories mentioning this entity, weighted by impact score. |
| Cross-niche links | When the same entity surfaces in our sibling networks, we link to those views to enrich context. |